CYP1A1, smoking and venous thromboembolism

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 702-708

  Zhu, Jin ^a   Zheng, Wen Jie ^b   Kong, Fan Cui ^a   Zhang, Wei Juan ^a   Wang, He Yao ^a   Wang, Chen ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

ARMS; Chinese; CYP1A1; Smoking; Venous thromboembolism

Indexed keywords

CONTRACEPTIVE AGENT; CYTOCHROME P450 1A1; ISOLEUCINE; VALINE;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MSPI GENE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; VENOUS THROMBOEMBOLISM;

AGED; CHINA; CYTOCHROME P-450 CYP1A1; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SMOKING; VENOUS THROMBOEMBOLISM;

EID: 77958142927     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0078     Document Type: Article

References (46)

1. Peterson D, Harward S, Lawson JH. Anticoagulation strategies for venous thromboembolism. Perspect Vasc Surg Endovasc Ther 2009; 21: 123-132.
2. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism: A metaanalysis involving120,000 cases and 180,000 controls. Thromb Haemost 2009; 102: 360-370.
3. Hansson PO, Eriksson H, Welin L, et al. Smoking and Abdominal Obesity. Arch Intern Med 1999; 159: 1886-1890.
4. Larsen TB, Sørensen HT, Gislum M, et al. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a populationbased nested case-control study. Thromb Res 2007; 120: 505-509. (Pubitemid 47094915)
5. Severinsen MT, Kristensen SR, Johnsen SP, et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 7: 1297-1303.
6. Androustsopoulos VP, TsatsakisAM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC cancer 2009; 9: 187.
7. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 2009; 41: 89-295.
8. Božina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 2009; 60: 217-242.
9. Shi X, Zhou S, Wang Z, et al. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung Cancer 2008; 59: 155-163.
10. Wright CM, Larsen JE, Colosimo ML, et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J 2010; 35: 152-159.
11. Shaffi SM, Shah MA, Bhat IA, et al. CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev. 2009;10: 651-656.
12. Syamala VS, Syamala V, Sheeja VR, et al. Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Invest 2010; 28: 304-311.
13. Singh AP, Shah PP, Ruwali M, et al. Polymorphism in cytochrome P4501A1 is significantly associated with head and neck cancer risk. Cancer Invest 2009; 27: 869-876.
14. Tai J, Yang M, Ni X, et al. Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet Cytogenet 2010;196: 76-82.
15. Luo X, Xu K. A solid phase method for extracting DNA from whole blood. Chin J Clin Lab Sci 2004; 22: 123-125.
16. Zhu J, Zhang W, Li Y, et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics 2010; 11: 113-119.
17. Ye S, Dhillon S, Ke X, et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001; 29: E88-8.
18. Iliakis G, Wang Y, Guan J, et al. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogen 2003; 22: 5834-5847. (Pubitemid 37176704)
19. Kastan M B, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
20. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407: 777-783.
21. Tampio M, Loikkanen J, Myllynen P, et al. Benzo[a]pyrene increases phosphorylation of p53 at serine 392 in relation to p53 induction and cell death in MCF-7 cells. Toxicol Lett 2008; 178: 152-159.
22. Lolhaug A, Øvrebø S, Mollerup S, et al. Role of cell signaling in B[a]P-induced apoptosis: characterization of unspecific effect of cell signaling inhibitors and apoptotic effects of B[a]P metabolites. Chemico-Biological Interactions 2005; 151: 110-119.
23. Solhaug A, Refsnes M, Låg M, et al. Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. Carcinogenesis 2004; 25: 809-819. (Pubitemid 38618535)
24. Lu X, Shao J, Li H, et al. Early whole-genome transcriptional response induced by Benzo[a]pyrene diol epoxide in a normal human cell line. Genomics 2009; 93: 332-342.
25. Lu KP, Hallberg LM, Tomlinson J, et al. Benzo(a)prene activates L1Md retrotransposon and inhibits DNA repair in vascular smooth muscle cells. Mutat Res 2000; 454: 35-44.
26. Annas A, Brittebo E, Hellman B. Evaluation of benzo(a)pyrene-induced DNA damage in human endothelial cells sing alkaline single cell gel electrophoresis. Mutat Res 2000; 471: 145-155.
27. Hakk H, Diliberto JJ, Birnbaum LS. The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice. Toxicol Appl Pharmacol 2009; 241: 119-126.
28. Lin P-H, Lin C-H, Huang C-C, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly (ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. Toxicol Lett 2007; 172: 146-158.
29. Lin P-H, Lin C-H, Huang C-C, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly (ADP-ribose) polymerase-1 activation by 17β-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression. Chem Res Toxicol 2008; 21: 1337-1347.
30. Chen Z-H, Hurh Y-J, Na H-K, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004; 25: 2005-2013.
31. Sul D, Kim H-S, Cho E-K, et al. 2,3,7,8-TCDD neurotoxicity in neuroblastoma cells is caused by increased oxidative sress, intracellular calcium levels, and tau phosphorylation. Toxicology 2009; 255: 65-71.
32. Cantrell SM, Joy-Schlezinger J, Stegeman JJ, et al. Correlation of 2,3,7,8-tetrachlorodibenzo- p-dioxin-induced apoptotic cell death in the embryonic vasculature with embryotoxicity. Toxcol Appl Pharmacol 1998; 148: 24-34.
33. Kawamura T, Yamashita I. Aryl hydrocarbon receptor is required for prevention of blood clotting and for the development of vasculature and bone in the embryos of Medaka Fish, Oryzias Iatipes. Zool Sci 2002; 19: 309-319.
34. Teraoka H, Dong W, Hiraga T. Zebrafish as a novel experimental model for developmental toxicology. Congential Anom 2003;43: 123-132.
35. Cantrell SM, Lutz LH, Tillitt DE, et al. Embryotoxicity of 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD): The embryonic vasculature is a physiological target for TCDD-induced DNA damage and apoptotic cell death in Medaka (Orizias Iatipes). Toxicol Appl Pharmacol 1996; 141: 23-34.
36. Korenaga T, Fukusato T, Ohta M, et al. Long-term effects of subcutaneously injected 2,3,7,8-tetrachlorodibenzo-p-dioxin on the liver of rhesus monkeys. Chemosphere 2007; 67: s399-404.
37. Barua RS, Sy F, Srikanth S, et al. Effect of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol 2010; 30: 75-79.
38. Undas A, Topór-Madry R, Tracz W, et al. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost 2009; 102: 1289-1291.
39. Kaehler J, Koeke K, Karstens M, et al. Impaaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Bio Med 2008; 44: 315-321.
40. Son DS, Rosman KK. 2,3,7,8-Tetrachlorodibenzo-p -dioxin (TCDD) induces plasminogen activator inhibitor-1 through an aryl hydrocarbon receptor-mediated pathway in mouse hepatoma cell lines. Arch Toxicol 2002; 76: 404-413.
41. Kasai A, Hiramatsu N, Hayakawa K, et al. High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 2006; 66: 7143-7150. (Pubitemid 44197692)
42. Lodovici M, Luceri C, Guglielmi F, et al. Benzo[a]pyrene Diolepoxide (BPDE)- DNA adduct levels in leukocyties of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidem Bioma 2004; 13: 1342-1348.
43. Alexandrov K, Cascorbi I, Rojas M, et al. CYP1A1 and GSTM1 genotypes affect Benzo[a]pyrene DAN adducts in smokers' lung: comparison with aromatic / hydrophobic adduct formation. Carcinogenesis 2002; 23: 1969-1977.
44. Rojas M, Cascorbi I, Alexandrov K, et al. Modulation of Benzo[a]pyrene diolepoxide- DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis 2000; 21: 35-41. (Pubitemid 30064141)
45. Rojas M, Alexandrov K, Cascorbi I, et al. High Benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics 1998; 8: 109-118. (Pubitemid 28227318)
46. Shantakumar S, Gammon MD, Eng SM, et al. Residential environmental exposures and other characteristics associated with detectable PAH-DAN adducts in peripheral mononuclear cells in a population-based sample of adult females. J Exp Anal Env Epid 2005; 15: 482-490. (Pubitemid 41643987)